La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Sunshine Biopharma Bilan de santé

Santé financière contrôle des critères 4/6

Sunshine Biopharma possède un total de capitaux propres de $23.5M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $29.3M et de $5.8M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$11.51m
Fonds propres	US$23.49m
Total du passif	US$5.81m
Total des actifs	US$29.30m

Mises à jour récentes de la santé financière

Recent updates

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Mar 14

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Jan 29

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sep 12

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de SBFM ( $25.7M ) dépassent ses passifs à court terme ( $5.3M ).

Passif à long terme: Les actifs à court terme de SBFM ( $25.7M ) dépassent ses passifs à long terme ( $511.6K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: SBFM est sans dette.

Réduire la dette: SBFM n'a actuellement aucune dette, mais nous ne pouvons pas comparer avec il y a 5 ans car nous n'avons pas de données pour cette période.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: SBFM dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: SBFM dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 55.2 % chaque année

Sunshine Biopharma Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Sunshine Biopharma Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101

Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Sunshine Biopharma Announces Update on Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Recent updates

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Sunshine Biopharma Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101

Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Sunshine Biopharma Announces Update on Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Share price stability

Sunshine Biopharma, Inc. Announces Executive Changes

Sunshine Biopharma, Inc. Announces Executive Changes

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Third quarter 2023 earnings: EPS exceeds analyst expectations

Sunshine Biopharma, Inc., Annual General Meeting, Dec 07, 2023

Sunshine Biopharma Receives 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Sunshine Biopharma, Inc. announced that it has received CAD 5 million in funding

First quarter 2023 earnings released: US$0.077 loss per share (vs US$0.23 loss in 1Q 2022)

Full year 2022 earnings released: US$1.76 loss per share (vs US$4.76 loss in FY 2021)

Sunshine Biopharma, Inc. (NasdaqCM:SBFM) announces an Equity Buyback for $2 million worth of its shares.

Sunshine Biopharma Receives Non-Compliance Notice From Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$1.59 loss in 3Q 2021)

Sunshine Biopharma, Inc. (NasdaqCM:SBFM) completed the acquisition of Nora Pharma Inc. from Malek Chamoun.

Sunshine Biopharma acquires Nora Pharma for C$30M

We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Second quarter 2022 earnings released: US$0.034 loss per share (vs US$1.20 loss in 2Q 2021)

Sunshine Biopharma reports 1H results

First quarter 2022 earnings released: US$0.23 loss per share (vs US$2.82 loss in 1Q 2021)

Sunshine Biopharma, Inc. Files Patent Application Announces mRNA Molecules

Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs

Sunshine Biopharma, Inc.’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells

Less than half of directors are independent

Sunshine Biopharma Common Stock Deleted from Other OTC

Sunshine Biopharma Mice Study for Covid-19 Treatment Progressing as Planned

Sunshine Biopharma, Inc.’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types

Sunshine Biopharma, Inc. announced that it has received $0.5 million in funding from RB Capital Partners, Inc.

Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a and Initiates QA/QC Testing

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines